Imugene (ASX: $IMU) initiates Phase 1 trial for bile tract cancer

Imugene Limited (ASX: $IMU) has successfully dosed the first patient in its Phase 1 trial for bile tract cancer (cholangiocarcinoma) at St. Vincent's Hospital, Melbourne. The trial aims to enroll 10 patients and has shown positive responses in gastrointestinal cancers, including a Complete Response (CR) in bile tract cancer.

Imugene Managing Director & CEO Leslie Chong's statement

Imugene Managing Director & CEO Leslie Chong expressed eagerness to explore the potential of VAXINIA in bile tract cancer following the positive results observed to date. The company looks forward to advancing to higher doses in the trial to gather further key data and make a genuine difference to patients in need of innovative treatment options.

Summary of Imugene's Phase 1 trial and outlook

Imugene Limited (ASX: $IMU) has made significant progress in its Phase 1 trial for bile tract cancer, with the first patient successfully dosed and positive responses observed in gastrointestinal cancers. The company's VAXINIA treatment has shown promising results, including a Complete Response (CR) in bile tract cancer, indicating the potential for innovative treatment options. With the trial expected to enroll a total of 10 patients and the FDA's Fast Track Designation, Imugene is poised to continue its advancements in cancer immunotherapies. The outlook for Imugene's immuno-oncology therapies remains optimistic, with the company's vision to transform and improve cancer treatment backed by a growing body of clinical evidence and peer-reviewed research.